(Q24244685)

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Randomized Comparison of Ceftriaxone versus Cefriaxone plus Amikacin for the Empirical Treatment of Infections in Patients with Altered Host Defense: Microbiological and Clinical Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Treatment of infections in hospitalized patients with ticarcillin plus clavulanic acid. A comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases--Neonatal Sepsis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Aspects of clinical trials with ceftazidime worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Treatment of skin, skin structure, bone, and joint infections with ceftazidime

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. Scandinavian Amikacin Once Daily Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Comparative efficacy of ceftazidime vs. carbenicillin and amikacin for treatment of neonatal septicemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

The epidemiology of hospitalization of elderly Americans for septicemia or bacteremia in 1991-1998. Application of Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Single or multiple daily doses of aminoglycosides: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Diagnosis and Management of Infective Endocarditis and Its Complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

The ACCP-SCCM consensus conference on sepsis and organ failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Factors Affecting Mortality of Gram-Negative Rod Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Single versus combination intravenous antibiotic therapy for people with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Development of resistance during antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Antimicrobial Therapy of Experimental Endocarditis Caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Community-acquired bacteremia in the elderly: a prospective study of 121 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Ceftazidime versus tobramycin/ticarcillin in treating hospital acquired pneumonia and bacteremia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Randomized multi center study comparing nephrotoxicity of ceftazidime versus the combination of piperacillin and netilmicin with and without furosemide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

[Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

[Comparison of the effectiveness of ceftazidime and cefazolin/tobramycin in patients with inflammatory diseases of the lower respiratory tract]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Nosocomial pneumonia: comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Randomized trial using piperacillin versus ampicillin and amikacin for treatment of premature neonates with risk factors for sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections. German and Austrian Imipenem/Cilastatin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

The microbiology and therapy of acute pelvic inflammatory disease in hospitalized patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A comparative study of two antibiotic regimens for the treatment of operative site infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Synergistic combinations of antibiotics in gram-negative bacillary infections.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Moxalactam Therapy vs. Standard Antimicrobial Therapy for Selected Serious Infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A randomized, controlled trial of cefoperazone vs. cefamandole-tobramycin in the treatment of putative, severe infections with gram-negative bacilli.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Gram-negative bacterial infections: a look at the past, a view of the present, and a glance at the future

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Comparative studies of ticarcillin and mezlocillin plus sisomicin in Gram-negative bacillary bacteraemia and bronchopneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Comparative study of the effects of ceftazidime compared with tobramycin plus cefamandole in the treatment of gall bladder empyema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A comparative study of the efficacy of ceftazidime versus cefazolin and tobramycin in patients with acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A therapeutic trial of cefotaxime versus penicillin-gentamicin for severe infections in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Cefotaxime in urinary tract infections--comparative clinical studies with gentamicin and with cefoxitin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Effectiveness of mezlocillin and endotracheally administered sisomicin with or without parenteral sisomicin in the treatment of Gram-negative bronchopneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Perioperative antibiotic therapy for penetrating injuries of the abdomen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Changing pattern of organ dysfunction in early human sepsis is related to mortality

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. British Thoracic Society Research Committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Initial treatment of sepsis in non-neutropenic patients: ceftazidime alone versus 'best guess' combined antibiotic therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Empiric therapy of infections in hematologic malignancies: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A randomised prospective comparison of cefotaxime versus netilmicin/penicillin for treatment of suspected neonatal sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

A prospective randomised comparison of cefotaxime vs. netilmicin vs. cefotaxime plus netilmicin in the treatment of hospitalised patients with serious sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

Aminoglycosides do not improve the efficacy of cephalosporins for treatment of acute pyelonephritis in women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003344.PUB2

7 January 2021

10.1002/14651858.CD003344.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16437452

1 reference

Consolidated OpenCitations Corpus – April 2017